Proof-of-principle that targeting CD147 is an attractive approach has been established by knockdown studies and anti-CD147 antibodies showing that loss of CD147 function markedly reduced the levels of both MCT-1 and MCT-4 proteins and impaired the growth of tumor xenografts in mice [131, 132]. Here, BSG is linked to neoplasm.